Abstract
Newly developed refractive multifocal IOLs by AMO1) were implanted into 38 eyes to compare their visual functions with those of diffractive multifocal IOLs currently approved for use. More than 20/20 (1.0) corrected far vision was determined 6 months postoperative in 90% of cases with refractive multifocal IOLs, and the same level vision was also seen in 90% with monofocal IOLs, and 79% with diffractive multifocal lenses. Of cases with diffractive multifocal IOLs, 81% resulted in more than 10/20 (0.5) near vision being corrected at far vision, while the same outcome appeared in 54% with refractive multifocal type. The results suggest a trend for refractive multifocal IOLs to work better for far vision and diffractive multifocal ones for near vision. A postoperative survey showed that 61% of patients with diffractive multifocal IOLs do not need glasses after surgery, nor do 50% with refractive multifocal type, nor 27% with monofocal type. Another survey concerned with glare indicated that 30% of patients with diffractive multifocal IOLs complained about this postoperative complication. The glare complication was noted in 14% with refractive multifocal IOLs and in 10% with monofocal IOLs. No significant difference was seen between the two types. It was concluded from the study that refractive multifocal IOLs, which have superior effect for far vision, have functions similar to monofocal IOLs, and this new type could be better utilized clinically.
1) ALLERGAN MEDICAL OPTICS: MODEL MPC-25 NB intraocular lens
